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Objective: To assess whether parathyroid hormone (PTH) (1-34) could improve the micro-structure of
subchondral bone, and retard cartilage degradation in a naturally occurring Osteoarthritis (OA) model.
Design: Forty-eight 1-month-old guinea pigs were divided into two groups: 32 were treated by normal
saline (NS) and sacriﬁced at 1, 3, 6 and 9 months of age; the other 16 received PTH (1-34) from 3 months,
and were sacriﬁced at 6 and 9 months. Masson staining and the Osteoarthritis Research Society Inter-
national (OARSI) grade scores were used to assess cartilage degradation. Immunohistochemistry analyses
of type-II collagen, matrix metalloproteinases-13 (MMP-13) and sclerostin (SOST) in the cartilage,
osteoprotegerin (OPG) and receptor activator of nuclear factor-kB ligand (RANKL) and PTH receptor
(PTH1R) in the cartilage and subchondral bone were performed. Subchondral bone micro-architecture
was assessed by micro-computed tomography (micro-CT).
Results: Histological analyses revealed OA occurred at 3 months of age and was more severe with
increasing age, and PTH (1-34) reduced the OARSI scores at 6 and 9 months of age. Micro-CT analysis
indicated that PTH (1-34) treatment increased the bone volume ratio and bone mineral density (BMD),
while retarding the subchondral trabecular bone micro-architectural changes from rod-like to plate-like.
Immunohistochemical staining demonstrated that PTH (1-34) treatment increased type-II collagen
expression and decreased SOST and MMP-13 expression in the cartilage, while elevating the PTH1R, OPG/
RANKL expression ratio in the cartilage and subchondral trabecular bone when compared with the
control groups.
Conclusions: PTH (1-34) can prevent cartilage damage progression and retard the deterioration of sub-
chondral trabecular bone in guinea pigs.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is one of the most prevalent joint disorders,
which has brought enormous challenges to social economics. OAL. Zhang, Department of Or-
United University, Tangshan,
Yan), tfm9911316@163.com
g), chengying2010@yeah.net
1953@163.com (Y.-Z. Zhang),
to this work.
ternational. Published by Elsevier Lhas been recently redeﬁned as a disease that affects thewhole joint,
including the articular cartilage and subchondral bone1e5.
Although it is unclear whether precedes or follows cartilage
damage, subchondral bone degeneration is an important feature of
the OA physiopathology. There is increasing evidence to support
the concept that skeletal adaptations antedate detectable alter-
ations in the structural integrity of the articular cartilage3,6. These
alterations include a progressive increase in subchondral plate
thickness, changes in the subchondral trabecular bone architecture,
formation of new bone at the joint margins (osteophytes), and
development of subchondral bone cysts. Skeletal changes in OA
may be associated with the differentiative adaptive capacity oftd. All rights reserved.
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damage. Because of this, optimal treatment options for OA should
entail both bone and cartilage protective effects.
Parathyroid hormone (PTH) acts as the most important regu-
lator of calcium homeostasis in the human body through its direct
action on bone and the kidneys7. Previous studies have shown
that intermittent administration of certain analogs of PTH pro-
duces an anabolic effect on bone8e11. Intriguingly, a new phar-
macological characteristic of PTH suggests it may have a possible
therapeutic beneﬁt in the treatment of OA12,13. A previous study
has revealed that PTH (1-34) acted on human articular chon-
drocytes to suppress their terminal differentiation and also sup-
pressed papain-induced OA in rats12. Further, recent research
using a rabbit osteochondral defects model, indicates that PTH (1-
34) improves articular cartilage surface architecture and inte-
gration, and subchondral bone reconstitution13. However, to date,
there have been no reports about the effect of PTH (1-34) on
primary OA.
Studies about primary OA progression in humans are difﬁcult
because of slow disease progression, and symptoms are often only
present in the later stages of the disease. As a consequence,
numerous animal models have been developed, but most are sec-
ondary OA models using mechanical instability or chemical inter-
vention to drive the disease14e18, which are not ideal models for
researching primary OA. Dunkin Hartley (DH) strain guinea pigs are
a well established and widely used naturally occurring OA model.
Importantly, the appearance of joint pathology in both guinea pigs
and humans is age-related; guinea pigs are subject to a variety of
well-recognized OA risk factors, which are shared with
humans19e22.
We therefore hypothesized that the bone-forming agent PTH (1-
34) may have therapeutic potential for treating OA. The present
study was designed to test this hypothesis by detecting the carti-
lage degeneration, extracellular matrix metabolism, and micro-
architecture changes in the subchondral bones of DH guinea pigs
with primary OA.
Materials and methods
Animal handling
All experiments were approved by Hebei United University
Animal Care and Use Committee. Forty-eight 1-month-old female
Dunkin Hartley guinea pigs (Vital River Experimental Animal
Technical Co., Ltd, Beijing, China) were fed a standard rodent diet
and housed in the Medical Research Animal Center. They were
randomly assigned into two groups as follows: 32 were treated by
Normal saline (NS) (1 ml/kg/day) for 5 days per week as control
group, and sacriﬁced at 1, 3, 6 and 9 months of age (eight animals
at each time point); the other 16 received subcutaneous injections
of PTH (1-34) (Sigma Chemical Co., USA) at a dosage of 15 mg/kg/
day for 5 days per week from 3 months of age, and were then
sacriﬁced at 6 and 9 months of age (eight animals at each time
point). The body weight of every animal in each group was
recorded.
Gross observations and specimen processing
After disarticulation, both femurs and tibias were cleaned and
their gross visual appearance recorded with a digital camera
(Canon 550D, Canon, Japan). The femurs were harvested for
parafﬁn sections; immunohistochemistry was conducted once fe-
murs were stained with Masson. The harvested tibias were ﬁxed in
70% ethanol for subchondral micro-computerized topographic
(micro-CT) testing.Tissue preparation and cartilage histopathological analysis
All femurs were ﬁxed in 4% paraformaldehyde for 48 h and then
decalciﬁed with 15% EDTA-Na2 (pH 7.4) at 4C for 6 weeks. The
distal end of femurs were dehydrated, embedded in parafﬁn, and
cut into 5-mm thick sections (according to standard protocols). Four
sections from each sample were stained with Masson. Then, three
color digital images from each section were recorded under light
microscopy (Olympus BX61, Olympus, Japan). Semi-quantitative
histopathological analysis was established according to the Osteo-
arthritis Research Society International (OARSI) score system using
ﬁve characteristics: articular cartilage structure, proteoglycan
content, cellularity, tidemark integrity, and osteophytes16. For each
animal the scoring was performed by a blinded observer using two
non-consecutive Masson stained sections.
Immunohistochemistry for type-II collagen, matrix
metalloproteinases-13 (MMP-13), sclerostin (SOST), PTH receptor
(PTH1R), osteoprotegerin (OPG) and receptor activator of nuclear
factor-kB ligand (RANKL)
To further clarify the cartilage degeneration and subchondral
bone changes, type-II Collagen, MMP-13 and SOSTexpression in the
cartilage, PTH1R, OPG and RANKL expression in the cartilage and
subchondral bonewere detected byway of immunohistochemistry.
Tissue sections were routinely deparafﬁnized, rehydrated and
repaired in complex phosphoesterasum for 10 min at 37C, and
then incubated overnight at 4C with anti-rabbit type-II collagen
(1:200), MMP-13 (1:150), OPG (1:100) and RANKL (1:100) (Boster
Corporation, Wuhan, China). The rest procedures were manipu-
lated according to the PV-6001 Two-Step IHC Detection Reagent
illustration (ZSGB-BIO Corporation, China); the color brown was
developed using DAB (ZSGB-BIO Corporation). The sections were
counterstained with hematoxylin. The sample appearing yellow or
brownish yellow was considered as positive staining. All sections
were semi-quantitatively analyzed by Image Pro Plus (IPP) version
6.0 software, and the integrated optical density (IOD) was
measured by the staining in six ﬁelds in each section on the images
at 400 magniﬁcation, the average IOD from three observers was
the ﬁnal observation result and used for statistical analysis.
Subchondral bone microstructural measurement
The proximal tibiae was scanned using a high-resolution micro-
CT system (SkyScan, Aartselaar, Belgium) to quantify the sub-
chondral bone plate thickness (deﬁned as starting from the calci-
ﬁed cartilage-bone junction and ending at the marrow space) and
micro-architecture of the subchondral trabecular bone, which
was deﬁned as the epiphyseal cancelous bone region 0.5 mm
beneath the subchondral plate of medial tibiae, with voxel size
9 mm, the energy and intensity were equal to 40 kVp and 250 mA,
respectively. The binary images were reconstructed to 3D for
qualitative and quantitative evaluations. The following 3D
morphometric parameters were calculated to describe the bone
mass and structure: bone mineral density (BMD), bone volume
ratio (BV/TV), trabecular thickness (Tb.Th), and the Structure Model
Index (SMI).
Statistical analysis
All data are expressed as the mean ± SD. Comparisons between
different age control groups were tested using a oneway analysis of
variance (ANOVA) and Fisher's least signiﬁcant difference (LSD) t-
test. Direct effects from treatment with PTH (1-34) were assessed
using an independent t test between PTH-treated and NS-treated
Table I
Body weight changes of the animals (g)
Group 1 month
(n ¼ 8)
3 months
(n ¼ 8)
6 months
(n ¼ 8)
9 months
(n ¼ 8)
Sham 325 ± 23 598 ± 21a 865 ± 38a,b 1062 ± 54a,b,c
PTH 331 ± 18 587 ± 26a 896 ± 43a,b 1137 ± 41a,b,c
a P < 0.05 vs 1 month.
b P < 0.05 vs 3 months.
c P < 0.05 vs 6 months.
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were considered to be statistically signiﬁcant.
Results
Number of observations included in the analysis
One animal in PTH treated group died for unknown reason, and
47 animals completed the study, groupmeanswere calculated from
eight specimen means except 9 months old PTH treated group,
which group means were calculated from seven specimen means.
Body weight
The body mass of each animal was measured weekly in the
control group and PTH (1-34) treatment group. As the animals' age
increased, they gained signiﬁcantly more weight. The weightFig. 1. Outline of the proximal tibia and histological ﬁndings of articular cartilage at distal fem
A, 1 month group; B, 3 months group; C, 6 months group; D, 9 months group; E, 6 months (PT
compared with 3 months group; &P < 0.05, compared with 6 months group; :P < 0.05, PTchanges in the PTH (1-34)-treated animals were comparable to, and
not signiﬁcantly different from the control group animals (Table I).Gross morphology, microscopic ﬁndings, and OARSI scoring of the
cartilage
The grossmorphology at 1 month of age showed that the guinea
pigs' articular surfaces were smooth, with an absence of osteophyte
formation in the femoral condyles and tibial plateaus. By 3 months
of age, mild discontinuous ﬁbrosis could be seen at the femoral
condyles and tibial plateaus. The animals displayed greater severity
of OAwith increasing age, 6-month-old guinea pigs showed obvious
cartilage ulceration, and at 9months of age, cartilage loss and typical
osteophyte were developed, the degeneration was particularly
pronounced in themedial condyle. Although animals in the PTH (1-
34)-treated grouphad rougher surfaces, ulceration and osteophytes,
these were not as serious as those in the control groups (Fig. 1).
With the Masson stain, the articular cartilage in 1-month-old
animals had a smooth surface and normal cellularity, and no abnor-
malitieswere noted in the chondrocytes or extracellularmatrix. Early
histological changes were observed in 3-month-old animals,
including focal proteoglycan loss andﬁbrillation.With increasingage,
6-month-old animals displayed more obvious chondrocyte death/
loss, ﬁbrillation and proteoglycan loss, and these degenerative
changes extended into deeper zone and cell cloning is prominent in
9-month-old animals. The cartilage samples in the PTH (1-34)-ur by Masson staining (200) and OARSI score of the articular cartilage in each group.
H) group; F, 9 months (PTH) group. *P < 0.05, compared with 1 month group; #P < 0.05,
H group compared with control group.
Fig. 2. Immunohistochemistry assay for type-II collagen and the changes of IOD in expression. (200) Immunohistochemical analysis showed that the protein levels of type-II
collagen in control group were weaker than those in the PTH treated group. A, 1 month group; B, 3 months group; C, 6 months group; D, 9 months group; E, 6 months (PTH) group;
F, 9 months (PTH) group; G, negative control staining. *P < 0.05, compared with 1 month group; #P < 0.05, compared with 3 months group; &P < 0.05, compared with 6 months
group; :P < 0.05, PTH group compared with control group.
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control groups, with slight articular cartilage degeneration (Fig. 2).
The OARSI score reﬂected pathological changes to the cartilage.
For the NS-treated groups, the OARSI scores increased with age
(P < 0.05). PTH (1-34) treatment reduced the OARSI score by 45%
and 53% at 6 and 9 months of age separately, in contrast to the
control group (Fig. 2).
Immunohistochemistry analysis
Immunohistochemistry assays were performed to evaluate the
protein levels of type-II collagen, MMP-13 and SOST in the cartilage.Fig. 3. Immunohistochemistry assay for PTH1R in the cartilage and subchondral bone and th
protein levels of PTH1R in cartilage and subchondral bone in control group were weaker th
group; D, 9 months group; E, 6 months (PTH) group; F, 9 months (PTH) group; G, negative c
months group; &P < 0.05, compared with 6 months group; :P < 0.05, PTH group compareThe analysis found a signiﬁcant decrease in type-II collagen
expression and an increase in the expression of MMP-13 and SOST
in the NS-treated groups as the age of the animals increased.
Guinea pigs treated with PTH (1-34) showed a 55% and 45% in-
crease in type-II collagen expression, and a 42% and 47% decrease in
MMP-13 expression, a 44% and 48% decrease in SOST expression at
6 and 9 months of age respectively, as compared with the control
groups (Figs. 3 and 4).
We also analyzed PTH1R, OPG and RANKL expression in the
articular cartilage and subchondral bone by immunohistochem-
istry. As in cartilage, guinea pigs treated with PTH (1-34) showed a
42% and 46% increase in PTH1R expression, a 21% and 32% increasee changes of IOD in expression. (200) Immunohistochemical analysis showed that the
an those in the PTH treated group. A, 1 month group; B, 3 months group; C, 6 months
ontrol staining. *P < 0.05, compared with 1 month group; #P < 0.05, compared with 3
d with control group.
Fig. 4. Immunohistochemistry assay for MMP-13 and SOST and the changes of IOD in expression (200). Immunohistochemical analysis showed that the protein levels of MMP-13
and SOST in control group were stronger than those in PTH treated group. A, 1 month group; B, 3 months group; C, 6 months group; D, 9 months group; E, 6 months (PTH) group; F,
9 months (PTH) group; G, negative control staining. *P < 0.05, compared with 1 month group; #P < 0.05, compared with 3 months group; &P < 0.05, compared with 6 months group;
:P < 0.05, PTH group compared with control group.
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at 6 and 9 months of age respectively. In the subchondral bone,
Guinea pigs treated with PTH (1-34) showed a 45% and 49% in-
crease in PTH1R expression, a 27% and 34% increase in OPG
expression and a 43% and 61% decrease in RANKL expression at 6
and 9 months of age respectively.
Further, we analyzed the ratio of OPG/RANKL in the articular
cartilage and subchondral bone. With increasing age, the NS-
treated group had a gradually decreasing ratio of OPG/RANKL in
both the cartilage and subchondral bone. Compared with the
control animals, increases in the OPG/RANKL ratio for cartilage and
subchondral bone in the PTH (1-34)-treated group were 31% and
37%, respectively, at 6 months, and 45% and 62%, respectively, at 9
months (Figs. 5e7).
Micro-CT parameters of the subchondral bone
Subchondral bonemicro-architecture was studied in each group
(Table II).
BMD increased with age and reached constant levels after 6
months. PTH (1-34)-treated animals showed higher values
compared with those of the control groups, with a signiﬁcant dif-
ference between animals aged 9 months.
Tb.Th increased with age, and BV/TV was highest at 3 months,
and then remained constant. With advanced age, the SMI were
markedly decreased. Comparedwith the control groups, PTH (1-34)
treatment increased BV/TV at both 6 months and 9 months, and
SMI at 9 months of age (Table II).
From 1 to 6 months of age, subchondral plate thickness of
control group were increased markedly (P < 0.05, Table II), and
remained fairly constant thereafter. Though PTH treated group hasslightly increased subchondral plate thickness, there is no differ-
ence when compared with control group.
Discussion
To the best of our knowledge, this study is the ﬁrst to determine
the effect of PTH (1-34) on cartilage degeneration in naturally
occurring OA. Our results support the hypothesis that PTH (1-34)
effectively protects against cartilage degradation in DH guinea pigs,
and also retards the deterioration of subchondral trabecular bone
micro-architecture.
DH guinea pigs have been shown to develop a temporally pre-
dictable, spontaneous knee OA with a high incidence histologically
and pathologically resemble OA in humans3; this includes evidence
of chondrocyte death, articular cartilage surface ﬁbrillation, and
osteophyte formation. Our study conﬁrmed age-related progressive
OA development in this guinea pig model, as indicated by the
Masson staining and OARSI score; cartilage degeneration appeared
at 3 months of age and progressed with increasing age, these
ﬁndings are similar to previous study23. Of note, systemic appli-
cation of PTH (1-34) directly prevent cartilage damage progression
and retard the deterioration of subchondral trabecular bone, as
PTH1R expression was signiﬁcantly up-regulated in both cartilage
and subchondral bone. PTH (1-34) treatment dramatically sup-
pressed the age-related increasing MMP-13, SOST expression in the
cartilage, coupled with increasing the expression of type-II collagen
in the cartilage, as well as elevating the ratio of OPG/RANKL
expression in both cartilage and subchondral bone.
The normal extracellular matrix consists of water and a speciﬁc
arrangement of macromolecules that support smooth cartilage
surfaces. The breakdown of type-II collagen is a key event in the
Fig. 5. Immunohistochemistry assay for OPG in the cartilage and subchondral bone and the changes of IOD in expression. (200) Immunohistochemical analysis showed that the
protein levels of OPG in cartilage and subchondral bone in control group were weaker than those in the PTH treated group. A, 1 month group; B, 3months group; C, 6 months group;
D, 9 months group; E, 6 months (PTH) group; F, 9 months (PTH) group; G, negative control staining. *P < 0.05, compared with 1 month group; #P < 0.05, compared with 3 months
group; &P < 0.05, compared with 6 months group; :P < 0.05, PTH group compared with control group.
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reduces the overall cartilage tensile strength. PTH (1-34)-treated
animals showed a higher expression of type II-collagen when
compared with the control group. Thus, PTH (1-34) may directly
contribute to extracellular matrix integrity. MMP-13 is thought to
be important catabolic enzymes responsible for extracellular ma-
trix turnover, and its expression is directly related to the degree of
OA. The inhibition of MMP-13 is considered to have a protective
effect in the maintenance of articular cartilage. In line with these
assumptions, we have shown that PTH (1-34) treatment decreases
the expression of MMP-13 in guinea pig cartilage. The present
ﬁndings suggest that PTH (1-34) treatment, at least in part, can
protect the integrity of the extracellular matrix during the devel-
opment of OA in guinea pigs.
SOST, is a member of the DAN/Cerberus protein family and acts
to inhibit bone morphogenetic protein (BMP) secretion from cells
in which it is co-expressed, and as a potent inhibitor of canonical
Wnt signaling by binding to LRP5/624,25. It has been demonstrated
that contrary to being an osteocyte-speciﬁc product, SOST is
expressed by articular chondrocytes and is regulated by IL-1a26 .But
no previous publications have investigated whether it plays a role
in global OA joint pathology. We have for the ﬁrst time demon-
strated an increase in SOST in chondrocytes restricted to the focal
area of cartilage degradation in naturally occurring OA model. Our
results shows SOST is increased in Guinea pig articular cartilage as
OA developed, which was similar to the results from some previous
studies that SOST is expressed by chondrocytes in mineralized
cartilage27, and in human end-stage OA28. While intermittent PTH
(1-34) treatment led to a decreased SOST expression when
compared with NS-treated animals. But further study is needed toinvestigate the exact role of SOST in PTH modulating cartilage
degeneration in naturally occurring OA model.
Subchondral bone has been recognized to play an important role
in the initiation and progression of OA. From a physiologic and
mechanical perspective, it is clear that the structural characteristics
of subchondral bone inﬂuence the functionality of the joint com-
plex as awhole. Ding et al.2 investigatedmicrostructural changes by
micro-CT and the 3D microstructural properties in early OA in
humans; they reported that the subchondral cancelous bone of the
medial tibia was more plate-like than was normal bone. Further-
more, using micro-CT, Ding et al.29 also investigated the sub-
chondral cancelous bone of the medial tibia in DH guinea pigs that
had been injected intra-articularly with high molecular weight
hyaluronan; these authors reported that this treatment protected
against cartilage degeneration and caused the bone structure to
become signiﬁcantlymore rod-like. Our study ﬁndings reﬂect these
observations.
Tb.Th increased with age, and BV/TV was highest at 3 months,
and then remained constant. With advanced age, the SMI were
markedly decreased. The subchondral bone plate was found to in-
crease in thickness from 3 to 6 months of age to a fairly constant
level retained until 9 months of age. It is conceivable that these
changes in combination with the microarchitectural changes in the
subchondral cancelous bone and will enhance subchondral bone
stiffness and thereby alter mechanical impact absorption capacity.
This alteration increases the charge and wear of the overlying
cartilage and could make this more prone to damage. In addition to
the higher bone mass, the increased SMI in the PTH (1-34)-treated
animals, showed more rod-like trabeculae than in the NS-treated
animals of the same age. This may protect cartilage from damage
Fig. 6. Immunohistochemistry assay for RANKL in the cartilage and subchondral bone and the changes of IOD in expression. (200) Immunohistochemical analysis showed that the
protein levels of RANKL in cartilage and subchondral bone in control group were stronger than those in the PTH treated group. A, 1 month group; B, 3 months group; C, 6 months
group; D, 9 months group; E, 6 months (PTH) group; F, 9 months (PTH) group; G, negative control staining. *P < 0.05, compared with 1 month group; #P < 0.05, compared with 3
months group; &P < 0.05, compared with 6 months group; :P < 0.05, PTH group compared with control group.
Fig. 7. The ratio of OPG/RANKL expression in the cartilage and subchondral bone. *P < 0.05, compared with 1 month group; #P < 0.05, compared with 3 months group; &P < 0.05,
compared with 6 months group; :P < 0.05, PTH group compared with control group.
Table II
Micro-architecture parameters of subchondral bone by micro-CT analysis
Parameters 1 month (n ¼ 8) 3 months (n ¼ 8) 6 months (n ¼ 8) 9 months (n ¼ 8) 6 months (PTH) (n ¼ 8) 9 months (PTH) (n ¼ 7)
BMD (g/cm2) 529.665 ± 29.410 622.013 ± 22.123a 685.549 ± 29.779a,b 709.337 ± 19.239a,b 706.072 ± 30.979 747.771 ± 19.238c
BV/TV (%) 40.010 ± 4.491 43.916 ± 3.259a 43.327 ± 1.825 42.500 ± 2.763 45.687 ± 3.590c 47.754 ± 3.062c
Tb.Th (mm) 96.111 ± 8.463 99.922 ± 8.21 110.399 ± 9.161a 117.952 ± 10.137a,b 113.323 ± 11.839 117.398 ± 9.531
Pl.Th (mm) 206.381 ± 10.573 269.794 ± 12.109a 338.521 ± 14.208a,b 347.912 ± 13.637a,b 342.363 ± 11.417 349.177 ± 16.565
SMI 1.534 ± 0.171 1.456 ± 0.323 1.087 ± 0.201a,b 0.878 ± 0.200a,b 1.256 ± 0.206 1.184 ± 0.227c
a P < 0.05 vs 1 month.
b P < 0.05 vs 3 months.
c P < 0.05 PTH group vs control group.
J.-y. Yan et al. / Osteoarthritis and Cartilage 22 (2014) 1869e1877 1875
J.-y. Yan et al. / Osteoarthritis and Cartilage 22 (2014) 1869e18771876during impact loading, because the rod-like trabeculae are able to
absorb higher-energy impact since they are more likely to yield
under load. However, this was more evident at 6 months of age
than at 9 months of age, the variations between control and PTH-
treatment animals were much reduced at 9 months of age, indi-
cating that as OA progresses, the protective effect observed with
PTH treatments becomes progressively reduced compared to the
control animals.
The deterioration of subchondral trabeculae bone during OA
development is considered to be triggered by enhanced bone
remodeling30. Abnormal OPG and RANKL levels, and consequently
an altered OPG and RANKL ratio, are reported to be involved in this
process31,32. Recent studies have offered some insight into the role
of the OPG/RANKL system in cartilage degeneration as OA pro-
gresses. It has been suggested that the OPG/RANKL pathway is
involved in OA progression by increasing catabolic factors33,34.
RANKL expression has been observed throughout all of the cartilage
zones of rabbits, and is especially increased in the calciﬁed cartilage
of chronic antigen-induced arthritis animals35. Upton et al.36 has
observed that the expression of RANKL protein, mRNA expression,
and the ratio of RANKL: OPGmRNA in human OA samples is greater
in grade 2 cartilage, when compared with grade 0 cartilage. Our
study directly measured OPG and RANKL expression in the articular
cartilage and subchondral bone. We found that the ratio of OPG/
RANKL decreased with age, indicating more active bone remolding
of the subchondral bone and cartilage metabolism, consistent with
previous studies35,36, while intermittent PTH (1-34) treatment led
to an increase in the OPG/RANKL ratio when compared with NS-
treated animals. In terms of the role of OPG/RANKL in cartilage
metabolism and subchondral bone remodeling, the increased ratio
of OPG/RANKL observed in the present study may have contributed
to the protective effect of PTH (1-34) on subchondral bone and
cartilage degradation.
The present study has also demonstrated that the increased
BMD of subchondral bone in PTH (1-34)-treated animals did not
affect its protective effect on cartilage. First, our results indicate that
enhanced BMD is probably due to the parallel increase in BV/TV. On
the other hand, PTH (1-34) treatment retarded the process of
subchondral bone remodeling from rod-like to plate-like; the
remodeling process is considered to be the crucial trigger for
increasing subchondral bone stiffness25. In this context, one of the
limitations of our study is a lack of direct evidence relating to the
changes in the biomechanical properties of subchondral bone.
Taken together, under the dosage and intervention period used
in the present study, prevention of further aggravation of cartilage
degradation in a naturally occurring OA model by the use of the
anabolic bone agent, PTH (1-34), is evidenced. Remarkably, this
beneﬁcial action on cartilage is accompanied with an inhibition of
subchondral bone remolding from rod-like to plate-like structures,
and thereby protected the subchondral micro-architecture from
deterioration. The underlying molecular mechanisms might be
related to regulation of expression of MMP-13, type-II collagen and
SOST in cartilage, and OPG, RANKL and PTH1R in both cartilage and
subchondral bone.
Author contributions
All authors made substantial contributions to study design,
analysis and interpretation of data, drafting the manuscript and
editing for important intellectual content of this article.
Role of funding source
The study is supported by National Natural Science foundation of
China (NSFC 31171136) and Hebei United University Doctor
Foundation.Conﬂict of interest
The authors acknowledge that there are no conﬂicts of interest
pertaining to this manuscript.
Acknowledgments
The authors would like to thank Hua-fang Xu and Hua Zhu for
assistance in animal procedures and histological analysis.
References
1. Bailey AJ, Mansell JP. Do subchondral bone changes exacerbate
or precede articular cartilage destruction in osteoarthritis of
the elderly? Gerontology 1997;43(5):296e304.
2. Ding M, Odgaard A, Hvid I. Changes in the three-dimensional
microstructure of human tibial cancellous bone in early oste-
oarthritis. J Bone Joint Surg Br 2003;85(6):906e12.
3. Goldring MB, Goldring SR. Articular cartilage and subchondral
bone in the pathogenesis of osteoarthritis. Ann N Y Acad Sci
2010;1192:230e7.
4. Bobinac D, Marinovic M, Bazdulj E, Cvijanovic O, Celic T,
Maric I, et al. Microstructural alterations of femoral head
articular cartilage and subchondral bone in osteoarthritis and
osteoporosis. Osteoarthritis Cartilage 2013;21(11):1724e30.
5. Cox LG, van Donkelaar CC, van Rietbergen B, Emans PJ, Ito K.
Alterations to the subchondral bone architecture during
osteoarthritis: bone adaptation vs endochondral bone forma-
tion. Osteoarthritis Cartilage 2013;21(2):331e8.
6. Hayami T, Pickarski M, Zhuo Y, Wesolowski GA, Rodan GA, le
Duong T. Characterization of articular cartilage and sub-
chondral bone changes in the rat anterior cruciate ligament
transection and meniscectomized models of osteoarthritis.
Bone 2006;38(2):234e43.
7. Lombardi G, Di Somma C, Rubino M, Faggiano A, Vuolo L,
Guerra E, et al. The roles of parathyroid hormone in bone
remodeling: prospects for novel therapeutics. J Endocrinol
Invest 2011;34(7 Suppl):18e22.
8. Zhang L, TakahashiHE, Inoue J, TanizawaT, EndoN,YamamotoN,
et al. Effects of intermittent administration of low dose human
PTH (1-34) on cancellous and cortical bone of lumbar vertebral
bodies on adult beagles. Bone 1997;21(6):501e6.
9. Podbesek R, Edouard C, Meunier PJ, Parsons JA, Reeve J,
Stevenson RW, et al. Effects of two treatment regimes with
synthetic human parathyroid hormone fragment on bone
formation and the tissue balance of trabecular bone in grey-
hounds. Endocrinology 1983;112(3):1000e6.
10. Hock JM, Gera I. Effects of continuous and intermittent
administration and inhibition of resorption on the anabolic
response of bone to parathyroid hormone. J Bone Miner Res
1992;7(1):65e72.
11. Uzawa T, Hori M, Ejiri S, Ozawa H. Comparison of the effects of
intermittent and continuous administration of human para-
thyroid hormone (1e34) on rat bone. Bone 1995;16(4):
477e84.
12. Chang JK, Chang LH, Hung SH, Wu SC, Lee HY, Lin YS, et al.
Parathyroid hormone 1e34 inhibits terminal differentiation of
human articular chondrocytes and osteoarthritis progression
in rats. Arthritis Rheumatol 2009;60(10):3049e60.
13. Orth P, Cucchiarini M, Zurakowski D, Menger MD, Kohn DM,
Madry H. Parathyroid hormone [1-34] improves articular
cartilage surface architecture and integration and subchondral
bone reconstitution in osteochondral defects in vivo. Osteo-
arthritis Cartilage 2013;21(4):614e24.
14. Bendele AM. Animal models of osteoarthritis. J Musculoskelet
Neuronal Interact 2001;1(4):363e76.
J.-y. Yan et al. / Osteoarthritis and Cartilage 22 (2014) 1869e1877 187715. Arunakul M, Tochigi Y, Goetz JE, Diestelmeier BW, Heiner AD,
Rudert J, et al. Replication of chronic abnormal cartilage
loading by medial meniscus destabilization for modeling
osteoarthritis in the rabbit knee in vivo. J Orthop Res
2013;31(10):1555e60.
16. Mohan G, Perilli E, Parkinson IH, Humphries JM, Fazzalari NL,
Kuliwaba JS. Pre-emptive, early, and delayed alendronate
treatment in a rat model of knee osteoarthritis: effect on
subchondral trabecular bone microarchitecture and cartilage
degradation of the tibia, bone/cartilage turnover, and joint
discomfort. Osteoarthritis Cartilage 2013;21(10):1595e604.
17. Mapp PI, Sagar DR, Ashraf S, Burston JJ, Suri S, Chapman V,
et al. Differences in structural and pain phenotypes in the
sodium monoiodoacetate and meniscal transection models of
osteoarthritis. Osteoarthritis Cartilage 2013;21(9):1336e45.
18. Cheng T, Zhang L, Fu X, Wang W, Xu H, Song H, et al. The
potential protective effects of calcitonin involved in coordi-
nating chondrocyte response, extracellular matrix, and sub-
chondral trabecular bone in experimental osteoarthritis.
Connect Tissue Res 2013;54(2):139e46.
19. Suri S, Walsh DA. Osteochondral alterations in osteoarthritis.
Bone 2012;51(2):204e11.
20. Bendele AM, Hulman JF. Effects of body weight restriction on
the development and progression of spontaneous osteoar-
thritis in guinea pigs. Arthritis Rheum 1991;34(9):1180e4.
21. Wei L, de Bri E, Lundberg A, Svensson O. Mechanical load and
primary guinea pig osteoarthrosis. Acta Orthop Scand
1998;69(4):351e7.
22. Huebner JL, Hanes MA, Beekman B, TeKoppele JM, Kraus VB.
A comparative analysis of bone and cartilage metabolism in
two strains of guinea-pig with varying degrees of naturally
occurring osteoarthritis. Osteoarthritis Cartilage 2002;10(10):
758e67.
23. Bendele AM, Hulman JF. Spontaneous cartilage degeneration
in guinea pigs. Arthritis Rheum 1988;31(4):561e5.
24. Krause C, Korchynskyi O, de Rooij KE, Weidauer SE, de
Gorter DJ, van Bezooijen RL, et al. Distinct modes of inhibition
by sclerostin on bone morphogenetic protein and Wnt
signaling pathways. J Biol Chem 2010;285(53):41614e26.
25. Semenov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and
a Wnt signaling inhibitor. J Biol Chem 2005;280(29):26770e5.
26. Chan BY, Fuller ES, Russell AK, Smith SM, Smith MM,
Jackson MT, et al. Increased chondrocyte sclerostin mayprotect against cartilage degradation in osteoarthritis. Osteo-
arthritis Cartilage 2011;19(7):874e85.
27. van Bezooijen RL, Bronckers AL, Gortzak RA, Hogendoorn PC,
van der Wee-Pals L, Balemans W, et al. Sclerostin in mineral-
ized matrices and van Buchem disease. J Dent Res 2009;88(6):
569e74.
28. Karlsson C, Dehne T, Lindahl A, Brittberg M, Pruss A,
Sittinger M, et al. Genome-wide expression proﬁling reveals
new candidate genes associated with osteoarthritis. Osteoar-
thritis Cartilage 2010;18(4):581e92.
29. Ding M, Danielsen CC, Hvid I. Effect of hyaluronan on three-
dimensional microarchitecture of subchondral bone tissues
in guinea pig primary osteoarthrosis. Bone 2005;36(3):
489e501.
30. Bellido M, Lugo L, Roman-Blas JA, Casta~neda S, Caeiro JR,
Dapia S, et al. Subchondral bone microstructural damage by
increased remodelling aggravates experimental osteoarthritis
preceded by osteoporosis. Arthritis Res Ther 2010;12(4):R152.
31. Tat SK, Pelletier JP, Velasco CR, Padrines M, Martel-Pelletier J.
New perspective in osteoarthritis: the OPG and RANKL system
as a potential therapeutic target? Keio J Med 2009;58(1):
29e40.
32. Tat SK, Pelletier JP, Lajeunesse D, Fahmi H, Lavigne M, Martel-
Pelletier J. The differential expression of osteoprotegerin (OPG)
and receptor activator of nuclear factor kappaB ligand (RANKL)
in human osteoarthritic subchondral bone osteoblasts is an
indicator of the metabolic state of these disease cells. Clin Exp
Rheumatol 2008;26(2):295e304.
33. Zhu S, Chen K, Lan Y, Zhang N, Jiang R, Hu J. Alendronate
protects against articular cartilage erosion by inhibiting sub-
chondral bone loss in ovariectomized rats. Bone 2013;53(2):
340e9.
34. Agarwal S, Misra R, Aggarwal A. Synovial ﬂuid RANKL and
matrix metalloproteinase levels in enthesitis related arthritis
subtype of juvenile idiopathic arthritis. Rheumatol Int
2009;29(8):907e11.
35. Sanchez C, Gabay O, Salvat C, Henrotin YE, Berenbaum F.
Mechanical loading highly increases IL-6 production and de-
creases OPG expression by osteoblasts. Osteoarthritis Cartilage
2009;17(4):473e81.
36. Upton AR, Holding CA, Dharmapatni AA, Haynes DR. The
expression of RANKL and OPG in the various grades of osteo-
arthritic cartilage. Rheumatol Int 2012;32(2):535e40.
